Abstract
The Response Assessment in Neuro-Oncology Criteria (RANO) Working Group recently published updated guidelines for assessing response to therapy in high-grade gliomas.[1][1] The goal of the group continues to be the development of a standardized method of response assessment. These guidelines are
Highlights
The validity of a research article is based on how close the study results are to the truth
The application of the best evidence into clinical practice requires a transition from thinking about the sensitivity and specificity of a diagnostic test to the likelihood or probability of the patient having the disease
If the pretest probability is above the clinician’s inclusion threshold for disease diagnosis or below the exclusion threshold, no further diagnostic testing is necessary because there is a reasonable degree of certainty that the patient does or does not have the disease
Summary
The validity of a research article is based on how close the study results are to the truth. The application of the best evidence into clinical practice requires a transition from thinking about the sensitivity and specificity of a diagnostic test to the likelihood or probability of the patient having the disease. The major modification proposed by the RANO guidelines is the assessment of increasing fluid-attenuated inversion recovery (FLAIR) signal intensity change as evidence of tumor progression.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.